APA (7th ed.) Citation

Siu, L. L., & Krauß, J. (2019). Safety and efficacy of Durvalumab with or without Tremelimumab in patients with PD-L1-low/negative recurrent or metastatic HNSCC: The phase 2 CONDOR randomized clinical trial. JAMA oncology, 5(2), . https://doi.org/10.1001/jamaoncol.2018.4628

Chicago Style (17th ed.) Citation

Siu, Lillian L., and Jürgen Krauß. "Safety and Efficacy of Durvalumab with or Without Tremelimumab in Patients with PD-L1-low/negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial." JAMA Oncology 5, no. 2 (2019). https://doi.org/10.1001/jamaoncol.2018.4628.

MLA (9th ed.) Citation

Siu, Lillian L., and Jürgen Krauß. "Safety and Efficacy of Durvalumab with or Without Tremelimumab in Patients with PD-L1-low/negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial." JAMA Oncology, vol. 5, no. 2, 2019, https://doi.org/10.1001/jamaoncol.2018.4628.